­
­
­
­

Inventi Impact: Pharmacokinetics & Pharmacodynamics

Articles

  • Inventi:pkd/27055/18
    Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing\nKlebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model
    01-Jan-1970 Research 2018 : October - December
    Jin Wang, Ji-tong He, Yan Bai, Rui Wang, Yun Cai

    Carbapenemase-producing Klebsiella pneumoniae is globally recognized as one of the greatest threats to public health, and\ncombination therapy may be the chemotherapeutic option. In the present study, we aimed to evaluate the antibacterial effects of\ncolistin/fosfomycin combination against carbapenemase-producing K. pneumoniae.The antibacterial effects were determined in a\none-compartment in vitro pharmacokinetic model over a period of 24 h.The initial inoculumwas 108 CFU/mL. Low, medium, and\nhigh

    How to Cite this Article
    Jin Wang, Ji-tong He, Yan Bai, Rui Wang, and Yun Cai, â??Synergistic Activity of Colistin/Fosfomycin Combination\nagainst Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model,â? BioMed Research\nInternational, vol. 2018, Article ID 5720417, 10 pages, 2018. https://doi.org/10.1155/2018/5720417, https://creativecommons.org/\nlicenses/by/4.0/.
    Download Full Text